Sharp Therapeutics Corp. is a preclinical-stage biotechnology company focused on developing therapeutics for genetic diseases using its CoreX technology suite. Key strengths include a solid return on equity (22.8%) and a strong current ratio (6.32), indicating good financial health and liquidity. However, the market capitalization of $43.26M and stagnant price suggest potential concerns regarding investor confidence or market perception. While the company shows promising metrics, its preclinical status may pose risks related to future product development and commercialization.
Loading financial metrics...
Company posted a loss of $-2.7M over the last year, representing Infinity% of revenue.
Fortress balance sheet: cash covers total debt 2.4×, providing significant financial flexibility.
Excellent liquidity with current ratio of 6.3x ensures operational stability.
Valuation, risk assessment, competitive positioning, and key insights — all in one report.
Other Biotechnology companies of a similar size
Based on 2025-Q2 (June 30, 2025)